Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. on behalf of Alnylam stockholders. The investigation concerns whether Alnylam violated federal securities laws or engaged in other unlawful business practices. The inquiry follows Alnylam's July 30, 2026 announcement of second-quarter 2026 financial results, in which the company lowered its total projected TTR net product revenues by approximately $200 million, citing learnings from the initial phase of its launch in the evolving ATTR-CM market. After the news, Alnylam's stock price dropped as much as $81.25 per share, or 28.35%, during intraday trading on July 30, 2026. The law firm encourages investors who suffered losses to contact partners Brandon Walker or Melissa Fortunato to discuss their legal rights.
Alnylam Pharmaceuticals IncCompany lowered revenue guidance and stock dropped 28% on Q2 results, prompting securities investigation.
